Jamie Near
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamie Near has a total of 513 co-authors. Here are the top co-authors by number of shared publications:
- Georg Oeltzschner
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
5 shared publications - Helge Jörn Zöllner
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
5 shared publications - Masoumeh Dehghani
Alberta children hospital research institute, University of Calgary, Canada
5 shared publications - Richard Anthony Edward Edden
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
5 shared publications - Cristina Cudalbu
CIBM Center for Biomedical Imaging, Lausanne, Switzerland
4 shared publications - Gabriel A. Devenyi
Douglas Mental Health University Institute
4 shared publications
Latest Publications
- Open Access
The Canadian Pediatric Imaging Platform (C-PIP) Reference Sample: Neuroimaging Protocol and Cross-site Validation for Harmonized Multimodal Pediatric Imaging
Understanding how the human brain matures from infancy through adolescence is essential for identifying factors that influence health outcomes. Magnetic resonance imaging (MRI) provides powerful tools for characterizing structural, microstructural, functional, and metabolic aspects of brain development; however, many pediatric imaging studies are constrained by small sample sizes, limited geographic diversity, lack of longitudinal measurement, restricted age ranges, and heterogeneous acquisition protocols. While recent large-scale neuroimaging consortia have begun to address these challenges, such resources remain limited in the Canadian context, creating a critical gap. The Canadian Pediatric Imaging Platform (C-PIP) has developed a multisite neuroimaging framework across three of Canada’s largest pediatric hospitals: Alberta Children’s Hospital (Calgary), Centre Hospitalier Universitaire Sainte-Justine (Montréal), and the Hospital for Sick Children (Toronto). These three sites were united through a national initiative, leveraging high-performance MRI systems to accelerate Canadian neurodevelopmental research. In addition, C-PIP has implemented a centralized data sharing infrastructure to facilitate open science and collaborative research across institutions. Here, we describe the development and implementation of a multimodal MRI acquisition protocol designed to support multimodal longitudinal studies of typical and atypical brain development spanning infancy through adolescence. Within-site stability and cross-site stability of C-PIP core MRI sequences were evaluated using a travelling-participant study. The C-PIP MRI protocol establishes a harmonized, multisite imaging framework that supports large-scale investigations of pediatric brain development and disorders. Highlights: The Canadian Pediatric Imaging Platform (C-PIP) is a national initiative acquiring longitudinal phenotyping and neuroimaging data from 820 children aged 0-18 years across three Canadian provinces (Alberta, Ontario and Québec). C-PIP has developed a harmonized, developmentally sensitive neuroimaging protocol to collect high-quality, comprehensive imaging data across multiple modalities. This paper outlines the development, considerations and implementation of the C-PIP neuroimaging protocol across sites. Preliminary cross-site validation analyses demonstrate good within- and between-site stability in neuroimaging measures. Graphical
Open AccessThe Canadian Pediatric Imaging Platform (C-PIP) Reference Sample: Neuroimaging Protocol and Cross-site Validation for Harmonized Multimodal Pediatric Imaging
Understanding how the human brain matures from infancy through adolescence is essential for identifying factors that influence health outcomes. Magnetic resonance imaging (MRI) provides powerful tools for characterizing structural, microstructural, functional, and metabolic aspects of brain development; however, many pediatric imaging studies are constrained by small sample sizes, limited geographic diversity, lack of longitudinal measurement, restricted age ranges, and heterogeneous acquisition protocols. While recent large-scale neuroimaging consortia have begun to address these challenges, such resources remain limited in the Canadian context, creating a critical gap. The Canadian Pediatric Imaging Platform (C-PIP) has developed a multisite neuroimaging framework across three of Canada’s largest pediatric hospitals: Alberta Children’s Hospital (Calgary), Centre Hospitalier Universitaire Sainte-Justine (Montréal), and the Hospital for Sick Children (Toronto). These three sites were united through a national initiative, leveraging high-performance MRI systems to accelerate Canadian neurodevelopmental research. In addition, C-PIP has implemented a centralized data sharing infrastructure to facilitate open science and collaborative research across institutions. Here, we describe the development and implementation of a multimodal MRI acquisition protocol designed to support multimodal longitudinal studies of typical and atypical brain development spanning infancy through adolescence. Within-site stability and cross-site stability of C-PIP core MRI sequences were evaluated using a travelling-participant study. The C-PIP MRI protocol establishes a harmonized, multisite imaging framework that supports large-scale investigations of pediatric brain development and disorders. Highlights: The Canadian Pediatric Imaging Platform (C-PIP) is a national initiative acquiring longitudinal phenotyping and neuroimaging data from 820 children aged 0-18 years across three Canadian provinces (Alberta, Ontario and Québec). C-PIP has developed a harmonized, developmentally sensitive neuroimaging protocol to collect high-quality, comprehensive imaging data across multiple modalities. This paper outlines the development, considerations and implementation of the C-PIP neuroimaging protocol across sites. Preliminary cross-site validation analyses demonstrate good within- and between-site stability in neuroimaging measures. Graphical
- 20 July 2026
- Published by Elsevier in Neurochemistry International
- Vol. 199
Early treatment with naproxen alters hippocampal metabolites in the TgF344-AD rat model of Alzheimer's disease
- 20 July 2026
- Published by Elsevier in Neurochemistry International
- Vol. 199
Early treatment with naproxen alters hippocampal metabolites in the TgF344-AD rat model of Alzheimer's disease
- 3 July 2026
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 39 (5) , 943
Correction: MRS4Brain: a software for preclinical proton and deuterium-based MR spectroscopic imaging data
- 3 July 2026
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 39 (5) , 943
Correction: MRS4Brain: a software for preclinical proton and deuterium-based MR spectroscopic imaging data
- Open Access
Choroid Plexus Enlargement is Associated with Disease Severity and Elevated White Matter Myo-inositol in Progressive Multiple Sclerosis
Introduction- Choroid plexus (CP) enlargement on brain MRI has been identified as an emerging neuroinflammatory biomarker in multiple sclerosis (MS), yet its relationship to downstream parenchymal neurochemical abnormalities remains unknown. Proton magnetic resonance spectroscopy ( 1 H MRS) enables non-invasive in vivo quantification of neurometabolites, making it well-suited to probe downstream consequences of CP pathology in MS. Methods- Ultra-high-field 7T 1 H MRS was performed in 45 people with MS (pwMS) (28 Relapsing Remitting MS, RRMS; 17 Progressive MS, PMS) and 43 age- and sex-matched healthy controls (HCs) in the posterior cingulate cortex (PCC) and centrum semiovale white matter (CSWM). CP volume, EDSS, and MS Functional Composite measures were also acquired. Group differences in metabolite concentrations were evaluated using Mann-Whitney U tests with correction for multiple comparisons, and associations between CP volume, altered metabolites, and clinical disability and functional measures were investigated. Results- Myo-inositol (mI) was significantly elevated and total N-acetylaspartate was reduced in both MS subtypes, in the CSWM. In PMS, CP volume was positively associated with CSWM mI/total creatine (tCr) (ρ = 0.63, p = 0.008), an association absent in RRMS. Across the combined MS cohort, CP volume correlated significantly with EDSS (ρ = 0.40, p = 0.006). Conclusions- WM mI/tCr was elevated and tNAA/tCr was reduced across MS phenotypes compared with controls, reflecting a dual metabolic signature consistent with concurrent glial overactivation and neuroaxonal compromise. Increased CP volume was associated with greater neurological disability across MS phenotypes. The association of CP enlargement with CSWM mI/tCr in PMS suggests a potential link between CP-mediated periventricular inflammation and progressive WM glial pathology. Collectively, these findings support CP volume as a clinically relevant, non-invasive biomarker and restoring CP integrity as a potential therapeutic target in PMS, where effective treatments remain limited.
Open AccessChoroid Plexus Enlargement is Associated with Disease Severity and Elevated White Matter Myo-inositol in Progressive Multiple Sclerosis
Introduction- Choroid plexus (CP) enlargement on brain MRI has been identified as an emerging neuroinflammatory biomarker in multiple sclerosis (MS), yet its relationship to downstream parenchymal neurochemical abnormalities remains unknown. Proton magnetic resonance spectroscopy ( 1 H MRS) enables non-invasive in vivo quantification of neurometabolites, making it well-suited to probe downstream consequences of CP pathology in MS. Methods- Ultra-high-field 7T 1 H MRS was performed in 45 people with MS (pwMS) (28 Relapsing Remitting MS, RRMS; 17 Progressive MS, PMS) and 43 age- and sex-matched healthy controls (HCs) in the posterior cingulate cortex (PCC) and centrum semiovale white matter (CSWM). CP volume, EDSS, and MS Functional Composite measures were also acquired. Group differences in metabolite concentrations were evaluated using Mann-Whitney U tests with correction for multiple comparisons, and associations between CP volume, altered metabolites, and clinical disability and functional measures were investigated. Results- Myo-inositol (mI) was significantly elevated and total N-acetylaspartate was reduced in both MS subtypes, in the CSWM. In PMS, CP volume was positively associated with CSWM mI/total creatine (tCr) (ρ = 0.63, p = 0.008), an association absent in RRMS. Across the combined MS cohort, CP volume correlated significantly with EDSS (ρ = 0.40, p = 0.006). Conclusions- WM mI/tCr was elevated and tNAA/tCr was reduced across MS phenotypes compared with controls, reflecting a dual metabolic signature consistent with concurrent glial overactivation and neuroaxonal compromise. Increased CP volume was associated with greater neurological disability across MS phenotypes. The association of CP enlargement with CSWM mI/tCr in PMS suggests a potential link between CP-mediated periventricular inflammation and progressive WM glial pathology. Collectively, these findings support CP volume as a clinically relevant, non-invasive biomarker and restoring CP integrity as a potential therapeutic target in PMS, where effective treatments remain limited.
- Open Access
- 26 June 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (8) , e70343
Metabolic Assessment in Human Pluripotent Stem Cell‐Derived Cerebral Organoids Using HR‐MAS NMR Spectroscopy
Brain metabolism is vital to healthy brain function and is often altered in disease; yet direct investigation in patients is challenging. Although animal models are commonly used for studying brain metabolism, their use is under increasing scrutiny due to concerns of animal welfare and model validity. Human pluripotent stem cell (hPSC)‐derived cerebral organoids (COs) present a unique opportunity to model human brain developmental and neuropathological processes, allowing for detailed metabolic characterization via multiple approaches. Here, we applied high‐resolution magic‐angle spinning (HR‐MAS) proton nuclear magnetic resonance ( 1 H‐NMR) spectroscopy to analyze metabolite levels in hPSC‐derived COs, establishing a pipeline to study neurometabolic pathways in these engineered human brain tissues. We identified and quantified 17 metabolites in hPSC‐derived COs at different stages of maturity. The high spectral quality (linewidth < 4 Hz, SNR > 65) allowed detection of metabolite levels in 85‐ to 312‐day‐old hPSC‐derived COs, which exhibited a metabolic profile similar to human fetal brain, with key distinguishing features relative to human adult brain, including: elevated lactate levels; approximately equimolar glutamate and glutamine levels; low N ‐acetylaspartate levels; and an abundance of hypotaurine. In summary, this study presents direct metabolic assessment in intact COs via HR‐MAS 1 H‐NMR spectroscopy. Our approach provides a platform for investigating human brain metabolism and its alteration in human brain models of neurodegeneration.
- 26 June 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (8) , e70343
Open AccessMetabolic Assessment in Human Pluripotent Stem Cell‐Derived Cerebral Organoids Using HR‐MAS NMR Spectroscopy
Brain metabolism is vital to healthy brain function and is often altered in disease; yet direct investigation in patients is challenging. Although animal models are commonly used for studying brain metabolism, their use is under increasing scrutiny due to concerns of animal welfare and model validity. Human pluripotent stem cell (hPSC)‐derived cerebral organoids (COs) present a unique opportunity to model human brain developmental and neuropathological processes, allowing for detailed metabolic characterization via multiple approaches. Here, we applied high‐resolution magic‐angle spinning (HR‐MAS) proton nuclear magnetic resonance ( 1 H‐NMR) spectroscopy to analyze metabolite levels in hPSC‐derived COs, establishing a pipeline to study neurometabolic pathways in these engineered human brain tissues. We identified and quantified 17 metabolites in hPSC‐derived COs at different stages of maturity. The high spectral quality (linewidth < 4 Hz, SNR > 65) allowed detection of metabolite levels in 85‐ to 312‐day‐old hPSC‐derived COs, which exhibited a metabolic profile similar to human fetal brain, with key distinguishing features relative to human adult brain, including: elevated lactate levels; approximately equimolar glutamate and glutamine levels; low N ‐acetylaspartate levels; and an abundance of hypotaurine. In summary, this study presents direct metabolic assessment in intact COs via HR‐MAS 1 H‐NMR spectroscopy. Our approach provides a platform for investigating human brain metabolism and its alteration in human brain models of neurodegeneration.
- Open Access
- 3 June 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 50, 104018
Age-dependent alterations in anterior cingulate excitation-inhibition balance in major depressive disorder revealed by 7-Tesla magnetic resonance spectroscopy
- 3 June 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 50, 104018
Open AccessAge-dependent alterations in anterior cingulate excitation-inhibition balance in major depressive disorder revealed by 7-Tesla magnetic resonance spectroscopy
- Open Access
- 14 May 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (3) , 1219-1234
SelExNet : A Self‐Supervised Physics‐Informed Framework for Multi‐Channel Joint RF and Gradient Waveform Optimization in 2D Spatially Selective Excitation
Purpose To introduce SelExNet: a self-supervised framework for two-dimensional spatially selective excitation that jointly optimizes radiofrequency (RF) pulses and gradient waveforms, and extends to multi-channel transmission MRI. Methods Building on prior RF-only and joint RF-gradient optimization approaches, SelExNet couples neural RF and gradient generators with a differentiable Bloch simulator to enable self-supervised pulse optimization without requiring pre-designed target pulses. The framework jointly designs RF pulses and parameterized variable-density spiral gradient waveforms for both single- and multi-channel transmission, with patient-specific adaptation using measured, previously unseen and maps. Results Joint optimization of RF and gradients improved excitation fidelity compared to RF-only optimization. In phantom experiments with synthetic field maps, pretrained pulses showed distortions, whereas fine-tuned pulses restored geometry and uniformity. In vivo studies demonstrated anatomically precise excitation, with fine-tuning improving sharpness and reducing off-target signal. Conclusion The proposed framework enables joint RF-gradient design and extends self-supervised pulse optimization to multi-channel transmission MRI. SelExNet achieves high-fidelity, anatomically precise excitation and demonstrates robustness to field inhomogeneities, offering a scalable pathway for ultra-high field imaging.- 14 May 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (3) , 1219-1234
Open AccessSelExNet : A Self‐Supervised Physics‐Informed Framework for Multi‐Channel Joint RF and Gradient Waveform Optimization in 2D Spatially Selective Excitation
Purpose To introduce SelExNet: a self-supervised framework for two-dimensional spatially selective excitation that jointly optimizes radiofrequency (RF) pulses and gradient waveforms, and extends to multi-channel transmission MRI. Methods Building on prior RF-only and joint RF-gradient optimization approaches, SelExNet couples neural RF and gradient generators with a differentiable Bloch simulator to enable self-supervised pulse optimization without requiring pre-designed target pulses. The framework jointly designs RF pulses and parameterized variable-density spiral gradient waveforms for both single- and multi-channel transmission, with patient-specific adaptation using measured, previously unseen and maps. Results Joint optimization of RF and gradients improved excitation fidelity compared to RF-only optimization. In phantom experiments with synthetic field maps, pretrained pulses showed distortions, whereas fine-tuned pulses restored geometry and uniformity. In vivo studies demonstrated anatomically precise excitation, with fine-tuning improving sharpness and reducing off-target signal. Conclusion The proposed framework enables joint RF-gradient design and extends self-supervised pulse optimization to multi-channel transmission MRI. SelExNet achieves high-fidelity, anatomically precise excitation and demonstrates robustness to field inhomogeneities, offering a scalable pathway for ultra-high field imaging. - Open Access
Assessing the clinical effects of accelerated iTBS across the spectrum of treatment-resistant depression: Clinical outcomes of the PRISM-UTRD trial
Importance: Conventional repetitive transcranial magnetic stimulation (rTMS) can be ineffective in individuals who have previously failed brain stimulation, ketamine and/or multiple lines of therapies. Modern accelerated rTMS protocols using image-guided targets have not been systematically investigated in these individuals. The goal of this study was to assess the feasibility and efficacy of personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) in patients with treatment-resistant depression (TRD) of varying refractoriness. Objective: To assess whether connectivity-guided, accelerated iTBS produces significant reductions in depression severity, and to what extent this benefit extends to ultra treatment-resistant depression (UTRD). Design: This was an open-label feasibility trial of connectivity-guided, accelerated iTBS in patients with TRD. Two distinct groups of participants were recruited from a neurosurgical-psychiatry clinic with UTRD and an interventional psychiatry clinic with TRD. Patients were stratified into a priori treatment-resistance subgroups. Patients received five days of open-label treatment. Outcome measures were collected immediately prior to and after treatment, as well as at 4- and 12-weeks post-treatment. Setting: This trial ( NCT05813093 ) was conducted between November 2023 and July 2025 at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. Participants: Patients with major depressive disorder. A total of 96 participants were screened, with 73 meeting eligibility criteria (UTRD=30, TRD=43). One withdrew due to inability to tolerate the baseline MRI, and the other withdrew voluntarily prior to treatment. Intervention: Participants underwent a neuronavigated accelerated iTBS (600 pulses) protocol using personalized left dorsolateral prefrontal cortex (dlPFC) targets derived from functional magnetic resonance imaging (fMRI), comprising eight daily treatments, repeated over five days. Main Outcomes: Primary outcomes were i) change in Hamilton Depression Rating Scale (HAM-D17) from baseline to the end of the fifth day of treatment, and ii) the difference in change in HAM-D17 between UTRD and TRD subgroups. Results: Connectivity-guided fMRI targeting yielded personalized targets clustered around the anterolateral dlPFC. Accelerated iTBS elicited rapid antidepressant effects (ΔHAM-D17 -9.01 [SD 6.06], t = -12.45, p < 0.001) regardless of treatment-resistance group (ΔHAM-D17 -9.64 [SD 5.94] vs -8.10 [SD 6.12], t = -1.05, p = 0.299), which were sustained up to 12 weeks after treatment. Overall response and remission rates at the end of treatment were 40.8% and 16.9%. Self-report scales revealed broad symptomatic relief outside of core depressive symptoms. Conclusions & Relevance: This study demonstrated that fMRI connectivity-guided, accelerated iTBS induces sustained antidepressant effects and broader psychiatric benefits in patients across the spectrum of TRD. In a cohort unlikely to respond to most antidepressant therapies, connectivity-guided, accelerated iTBS offers a safe, well-tolerated option that can achieve benefit, or when ineffective, allow patients to expeditiously proceed with subsequent therapies than conventional rTMS. Trial Registration: This clinical trial was registered at clinicaltrials.gov with NCT05813093 .
Open AccessAssessing the clinical effects of accelerated iTBS across the spectrum of treatment-resistant depression: Clinical outcomes of the PRISM-UTRD trial
Importance: Conventional repetitive transcranial magnetic stimulation (rTMS) can be ineffective in individuals who have previously failed brain stimulation, ketamine and/or multiple lines of therapies. Modern accelerated rTMS protocols using image-guided targets have not been systematically investigated in these individuals. The goal of this study was to assess the feasibility and efficacy of personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) in patients with treatment-resistant depression (TRD) of varying refractoriness. Objective: To assess whether connectivity-guided, accelerated iTBS produces significant reductions in depression severity, and to what extent this benefit extends to ultra treatment-resistant depression (UTRD). Design: This was an open-label feasibility trial of connectivity-guided, accelerated iTBS in patients with TRD. Two distinct groups of participants were recruited from a neurosurgical-psychiatry clinic with UTRD and an interventional psychiatry clinic with TRD. Patients were stratified into a priori treatment-resistance subgroups. Patients received five days of open-label treatment. Outcome measures were collected immediately prior to and after treatment, as well as at 4- and 12-weeks post-treatment. Setting: This trial ( NCT05813093 ) was conducted between November 2023 and July 2025 at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. Participants: Patients with major depressive disorder. A total of 96 participants were screened, with 73 meeting eligibility criteria (UTRD=30, TRD=43). One withdrew due to inability to tolerate the baseline MRI, and the other withdrew voluntarily prior to treatment. Intervention: Participants underwent a neuronavigated accelerated iTBS (600 pulses) protocol using personalized left dorsolateral prefrontal cortex (dlPFC) targets derived from functional magnetic resonance imaging (fMRI), comprising eight daily treatments, repeated over five days. Main Outcomes: Primary outcomes were i) change in Hamilton Depression Rating Scale (HAM-D17) from baseline to the end of the fifth day of treatment, and ii) the difference in change in HAM-D17 between UTRD and TRD subgroups. Results: Connectivity-guided fMRI targeting yielded personalized targets clustered around the anterolateral dlPFC. Accelerated iTBS elicited rapid antidepressant effects (ΔHAM-D17 -9.01 [SD 6.06], t = -12.45, p < 0.001) regardless of treatment-resistance group (ΔHAM-D17 -9.64 [SD 5.94] vs -8.10 [SD 6.12], t = -1.05, p = 0.299), which were sustained up to 12 weeks after treatment. Overall response and remission rates at the end of treatment were 40.8% and 16.9%. Self-report scales revealed broad symptomatic relief outside of core depressive symptoms. Conclusions & Relevance: This study demonstrated that fMRI connectivity-guided, accelerated iTBS induces sustained antidepressant effects and broader psychiatric benefits in patients across the spectrum of TRD. In a cohort unlikely to respond to most antidepressant therapies, connectivity-guided, accelerated iTBS offers a safe, well-tolerated option that can achieve benefit, or when ineffective, allow patients to expeditiously proceed with subsequent therapies than conventional rTMS. Trial Registration: This clinical trial was registered at clinicaltrials.gov with NCT05813093 .
- Open Access
- 10 April 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (2) , 516-529
The Impact and Reliability of Tissue Segmentation on In Vivo Magnetic Resonance Spectroscopy Metabolite Quantification
Purpose: Quantification of metabolite concentrations using MRS requires tissue‐dependent signal corrections. Accurate estimation of voxel tissue composition is therefore essential. Commonly used brain tissue segmentation tools differ in their algorithms and implementation, potentially introducing variability in MRS‐derived concentration estimates. This study investigates the impact and reliability of tissue segmentation on metabolite quantification. Methods: Three segmentation tools (ANTs, FSL, SPM) were evaluated using an in vivo test–retest MRI/MRS dataset. Voxelwise GM/WM/CSF fractions were applied to compute tissue‐corrected total creatine (tCr) concentrations. Linear mixed‐effects modeling, variance‐component partitioning, and intraclass correlation coefficients (ICCs) quantified tool‐, session‐, and participant‐related variance under permutation scenarios that isolated segmentation‐ and MRS‐related effects. As a benchmark for segmentation performance, comparisons with manually segmented data were conducted across three brain regions. Results: Segmentation tools produced systematically different tissue fractions that propagated into differences in tCr concentration estimates. Variance partitioning attributed 56.8%, 50.0%, and 51.3% of total tCr concentration variability to segmentation tool across the three permutations, with participant‐specific factors accounting for 34.7%, 36.2%, and 28.5%, respectively. When segmentation variability was held constant, test–retest reliability was high (ICC > 0.8) but dropped to ∼0.5 when both segmentation and MRS variability varied. Agreement with manual segmentation was region‐ and tool‐dependent, with the lowest agreement in the thalamus. Conclusion: Tissue segmentation contributes substantially to the variability in MRS‐derived metabolite concentration estimates. These results underscore the need for transparent segmentation reporting and data sharing to ensure reproducibility and cross‐study comparability in MRS research.
- 10 April 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (2) , 516-529
Open AccessThe Impact and Reliability of Tissue Segmentation on In Vivo Magnetic Resonance Spectroscopy Metabolite Quantification
Purpose: Quantification of metabolite concentrations using MRS requires tissue‐dependent signal corrections. Accurate estimation of voxel tissue composition is therefore essential. Commonly used brain tissue segmentation tools differ in their algorithms and implementation, potentially introducing variability in MRS‐derived concentration estimates. This study investigates the impact and reliability of tissue segmentation on metabolite quantification. Methods: Three segmentation tools (ANTs, FSL, SPM) were evaluated using an in vivo test–retest MRI/MRS dataset. Voxelwise GM/WM/CSF fractions were applied to compute tissue‐corrected total creatine (tCr) concentrations. Linear mixed‐effects modeling, variance‐component partitioning, and intraclass correlation coefficients (ICCs) quantified tool‐, session‐, and participant‐related variance under permutation scenarios that isolated segmentation‐ and MRS‐related effects. As a benchmark for segmentation performance, comparisons with manually segmented data were conducted across three brain regions. Results: Segmentation tools produced systematically different tissue fractions that propagated into differences in tCr concentration estimates. Variance partitioning attributed 56.8%, 50.0%, and 51.3% of total tCr concentration variability to segmentation tool across the three permutations, with participant‐specific factors accounting for 34.7%, 36.2%, and 28.5%, respectively. When segmentation variability was held constant, test–retest reliability was high (ICC > 0.8) but dropped to ∼0.5 when both segmentation and MRS variability varied. Agreement with manual segmentation was region‐ and tool‐dependent, with the lowest agreement in the thalamus. Conclusion: Tissue segmentation contributes substantially to the variability in MRS‐derived metabolite concentration estimates. These results underscore the need for transparent segmentation reporting and data sharing to ensure reproducibility and cross‐study comparability in MRS research.
- Open Access
- 8 April 2026
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 39 (3) , 361-379
MRS4Brain: a software for preclinical proton and deuterium-based MR spectroscopic imaging data
Objectives: Magnetic resonance spectroscopic imaging (MRSI) is a non-invasive technique for probing metabolism. MRSI enables spatial mapping of metabolite distributions, offering insights into regional metabolic heterogeneity that single-voxel spectroscopy (SVS) cannot capture. However, MRSI produces large multidimensional datasets and requires complex processing pipelines, limiting reproducibility and accessibility. While human studies benefit from advanced processing tools, similar developments in preclinical research remain scarce, highlighting a demand for practical tools accessible to non-experts. Furthermore, recent advances in deuterium-based MRSI have opened metabolic pathway studies, introducing additional dimensions for kinetic information and specific positional labeling, thus substantially increasing dataset complexity and analysis demands. Methods: To address these needs, we introduce the MRS4Brain Toolbox , a freely available MATLAB-based platform for preclinical MRSI supporting proton, deuterium, and other nuclei, with extended functionalities for SVS and diffusion-weighted spectroscopy. Results: The toolbox integrates reconstruction, preprocessing, quantification, quality control, brain segmentation automatically overlaid on metabolite maps, modeling, and statistical analysis into unified workflows accessible via a graphical interface. Conclusion: By streamlining data processing and reducing technical barriers, MRS4Brain Toolbox promotes reproducibility, harmonization, and broader adoption of basic and advanced spectroscopic techniques in preclinical studies, ultimately facilitating translational metabolic research.
- 8 April 2026
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 39 (3) , 361-379
Open AccessMRS4Brain: a software for preclinical proton and deuterium-based MR spectroscopic imaging data
Objectives: Magnetic resonance spectroscopic imaging (MRSI) is a non-invasive technique for probing metabolism. MRSI enables spatial mapping of metabolite distributions, offering insights into regional metabolic heterogeneity that single-voxel spectroscopy (SVS) cannot capture. However, MRSI produces large multidimensional datasets and requires complex processing pipelines, limiting reproducibility and accessibility. While human studies benefit from advanced processing tools, similar developments in preclinical research remain scarce, highlighting a demand for practical tools accessible to non-experts. Furthermore, recent advances in deuterium-based MRSI have opened metabolic pathway studies, introducing additional dimensions for kinetic information and specific positional labeling, thus substantially increasing dataset complexity and analysis demands. Methods: To address these needs, we introduce the MRS4Brain Toolbox , a freely available MATLAB-based platform for preclinical MRSI supporting proton, deuterium, and other nuclei, with extended functionalities for SVS and diffusion-weighted spectroscopy. Results: The toolbox integrates reconstruction, preprocessing, quantification, quality control, brain segmentation automatically overlaid on metabolite maps, modeling, and statistical analysis into unified workflows accessible via a graphical interface. Conclusion: By streamlining data processing and reducing technical barriers, MRS4Brain Toolbox promotes reproducibility, harmonization, and broader adoption of basic and advanced spectroscopic techniques in preclinical studies, ultimately facilitating translational metabolic research.